Cargando…

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours

The blood–brain barrier is a major obstacle for the chemotherapeutic drugs to effectively reach primary or secondary brain tumours. Stealth® liposomal drugs are highly accumulated in tumoural tissues. In the present study we investigated the relative accumulation of(99m)Tc-DTPA radiolabelled stealth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koukourakis, M I, Koukouraki, S, Fezoulidis, I, Kelekis, N, Kyrias, G, Archimandritis, S, Karkavitsas, N
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408790/ https://www.ncbi.nlm.nih.gov/pubmed/11044350 http://dx.doi.org/10.1054/bjoc.2000.1459

Ejemplares similares

Reply: (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Koukourakis, M I
Publicado: (2002)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection
por: Koukourakis, M I, et al.
Publicado: (2002)

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts
por: Eikenes, L, et al.
Publicado: (2005)

A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx (®) in advanced breast cancer
por: Li, Yinjuan, et al.
Publicado: (2022)

Pegylated Liposomal Doxorubicin (Caelyx(®)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
por: Dellapasqua, Silvia, et al.
Publicado: (2021)

Comparative plasma and tissue distribution of Sun Pharma’s generic doxorubicin HCl liposome injection versus Caelyx(®) (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague–Dawley rats
por: Burade, Vinod, et al.
Publicado: (2017)

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine
por: Verreault, Maite, et al.
Publicado: (2011)

Targeting doxorubicin encapsulated in stealth liposomes to solid tumors by non thermal diode laser
por: Ghannam, Magdy M., et al.
Publicado: (2016)

Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models
por: Burade, Vinod, et al.
Publicado: (2017)

Surface Engineering of Liposomes for Stealth Behavior
por: Nag, Okhil K., et al.
Publicado: (2013)

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
por: Goebel, F. D., et al.
Publicado: (1996)

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
por: Hessmann, E, et al.
Publicado: (2018)

Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model
por: Gasselhuber, Astrid, et al.
Publicado: (2012)

Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation
por: Begum, M. Yasmin, et al.
Publicado: (2022)

Intratumoural administration and tumour tissue targeting of cancer immunotherapies
por: Melero, Ignacio, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

The Benefits of Prone SPECT Myocardial Perfusion Imaging in Reducing Both Artifact Defects and Patient Radiation Exposure
por: Stathaki, Maria, et al.
Publicado: (2015)

Intratumour heterogeneity in microRNAs expression regulates glioblastoma metabolism
por: Alfardus, Huda, et al.
Publicado: (2021)

Flurbiprofen-Loaded Stealth Liposomes: Studies on the Development, Characterization, Pharmacokinetics, and Biodistribution
por: Begum, MY, et al.
Publicado: (2012)

Spatiotemporal Control of Doxorubicin Delivery from “Stealth-Like” Prodrug Micelles
por: Kong, Li, et al.
Publicado: (2017)

CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice
por: Jubair, Luqman, et al.
Publicado: (2021)

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma
por: Akgül, Seçkin, et al.
Publicado: (2019)

Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
por: Immordino, Maria Laura, et al.
Publicado: (2006)

Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics
por: Kommineni, Nagavendra, et al.
Publicado: (2022)

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)
por: Poveda, A., et al.
Publicado: (2005)

Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists
por: Burn, Olivia K., et al.
Publicado: (2020)

Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine
por: Chen, Jun, et al.
Publicado: (2012)

Opsonin-Deficient Nucleoproteic Corona Endows UnPEGylated Liposomes with Stealth Properties In Vivo
por: Giulimondi, Francesca, et al.
Publicado: (2022)

Inclusion Complex between Local Anesthetic/2-hydroxypropyl-β-cyclodextrin in Stealth Liposome
por: Souza, Gredson Keiff, et al.
Publicado: (2022)

TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
por: van der Veen, A H, et al.
Publicado: (2000)

Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
por: Nguyen, Phuong H. D., et al.
Publicado: (2021)

A Mathematical Model for Thermosensitive Liposomal Delivery of Doxorubicin to Solid Tumour
por: Zhan, Wenbo, et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
por: Ellis, Hayley P., et al.
Publicado: (2015)

Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas
por: Xu, Dahua, et al.
Publicado: (2023)

The Stealth Virus
por: Tang, Julian W.
Publicado: (2013)

Encapsulation into Stealth Liposomes Enhances the Antitumor Action of Recombinant Cratylia mollis Lectin Expressed in Escherichia coli
por: da Cunha, Cássia R. A., et al.
Publicado: (2016)

Multidimensional intratumour heterogeneity in neuroblastoma
por: von Stedingk, Kristoffer, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_apd38ev26amoeaggch732kevq4